2015.9.19-21 Wolrd Pheromonicin Conference 第一届信息菌素类药物研究与应用研讨会

2015年前沿科技国际孵化器引进北京经济技术开发区的项目P7:首次举办北京生物技术和新医药产业促进中心承办的第十九届北京国际生物医药产业发展论坛的前导分会场,第一届信息菌素类药物研究与应用研讨会”,吸引了来自世界各地研究如何应对抗生素耐药难题的顶尖科学家、产业家的积极参与,他们的目标只有一个,论证信息菌素是不是人类应对细菌耐药——对人类健康严重威胁的一个重大突破,纵论这一成果将会给抗生素乃至医药产业带来哪些历史性的变化。Frontier Technologies International Development, Ltd. Portfolio 7 entering Beijing Economic-technological Development Area (BDA) in 2015: As the foreword meeting of the 19th Beijing International Healthcare Industry Forum, the First International Workshop on the Pheromonicin Drug Development Platform has attracted world top scientists and industrialists who are researching on how to fight problems of antibiotic-resistance. In this Workshop, participants’ sole mission is to validate if Pheromonicin is a major breakthrough of people versus drug-resistant bacteria, which is a serious threat to the healthy mankind. Let’s discuss how this achievement will change antibiotic and further the medicine industry with a historical impact under making.

Continue reading

2015.3 Pheromonicin Institute (Beijing) 信息菌素研究院成立


  • 对主流新药研发的国际制药公司提供研发授权。
  • 对成熟制药公司销售技术授权。
  • 以技术授权与具有区域市场影响力的企业交换股权。
  • 以技术授权和知识投入控股创业公司。



2014.7 Gordon Research Conference 戈登研究会耐药性专题分会 Goldon Research Conferences

2014年7月13-18日在美国缅因州Sunday River Resort由Sally Blower & Amy C. Anderson主持召开 Gordon Research conferences”。该会议主题为“耐药问题”(Drug Resistance)
会议的发起和单位为:Gorden Research Confenrences ; Carl Storm Underrepresented Minority Fellowship , NIH, Merck , Novartis ,Cubist and Promiliad。

1、中国科学家,四川大学丘小庆教授因其在改造和利用大肠菌素并发明信息菌素方面取得的卓越成果应邀出席了此次会议。是出席此次会议唯一的大陆科学家。与会科学家对丘小庆教的研究成果给予高度评价。“Drug Resistance”专题讨论会的发起人,长期从事细菌素-大肠杆菌素研究,一直大力宣传和推动细菌素理论和应用前景,美国University Massachusetts教授, 马赛诸塞州科学院主席,Dr. Margaret Riley认为丘小庆教授“信息菌素”的研究成果将引领世界制药业的一次的浪潮。(I have finished reading the data and find the entire package very impressive. I think the potential for this work to lead a surge in industrial interest is quite high.)大会主席 Sally Blower认为:“His work sounds incredible”。下一届会议主席,华盛顿大学化学系主任和教授,从事疟原虫研究的Dr. Pradip Rathod 认为:“ your work is truly inspiring , If we ever get chance to work together on Pf, it would be pure joy. Its an important problem and your imagination will lead us to places we have never been”.

细菌素具有高效率(杀菌效力达 nM级别)、可在体内工作、无毒性、易用分子生物学手段改造等特点,所以其开发进展最为迅速。细菌素是细菌产生的一种外毒素,对同种内其他株系具有致死性。研究得最为透彻的细菌素是大肠杆菌分泌的细菌素:大肠菌素。目前认为大肠菌素是维持肠道菌群的多样性和进化的调节动力。
60余年前, 青霉素发明者、诺贝尔奖得主 Florey 等已发现大肠菌素抗菌活性极强、能在血循环中工作、稳定性好、对血液和器官无毒性、对肠道菌群亦无影响。同时他也发现由于大肠菌素固有的靶向性,只能识别大肠杆菌,而不能识别其他致病菌。因此人们放弃了将大肠菌素开发成为抗生素的努力。
数位科学家,包括小庆教授对大肠菌素进行了一系列的基础研究:1978年 Finkelstein等发现E1族大肠菌素是在靶细菌的胞膜上形成致死性的离子通道,这是与现用抗生素完全不同的一种物理杀菌机制。1986年Konisky等完成了大肠菌素Ia的DNA和氨基酸序列测定。1996年丘小庆和Finkelstein等完成了大肠菌素Ia致死性离子通道的跨膜结构研究,1997年Weiner等完成了大肠菌素Ia的立体结构研究。这些工作为开发大肠菌素奠定了坚实的理论基础。
丘小庆教授在前人工作基础上,经过二十余年的努力,成功的改变了大肠菌素固有的靶向性, 设计出了一系列可对抗革兰氏阳性和阴性耐药菌的新型抗生物质 — 信息菌素。

2013: Modern Facility Built in Beijing 现代化设施建设

2013 信息菌素靶向药物工程中心设施投入使用。该设施包括科研、设计、实验室、室内植物实验地和中试原药生产等功能,建筑面积4,300平方米所在地:北京市海淀区苏家坨镇前沙涧村东,北京科润维德生物技术有限公司的千亩园区内
New facility of Pheromonicin Guided Drug (Beijing) Engineering Develop Center is under construction, and to be open late 2013. The Facility hosts the Center’s functions of R&D, designs, lab experiments, in-door plantation test ground, and pilot drug production, etc. Continue reading

2013: US California Incorporation 美国子公司成立

2013 在洛杉矶设美国公司实体
Pheromonicin Biotech Group is forming a US California State corporation in June 2013. Its headquarter is located in a popular Los Angless’ central vicinity, with convenience for operation and recognition of international businesses.
Formation of PBL (USA) is aiming development of US-onshore and world-market businesses of Pheromonicin® drugs. Continue reading

2013: Primate test started in UIC 灵长类试验 伊利诺伊大学芝加哥分校

Anti Tuberculosis Drug Development

Pheromonicin Biotech USA, Inc. is sponsoring primate experiments in a lab in University of Illinois at Chicago (UIC). The experiment plan is designed under USDA’s conditional proof. UIC planned to accomplishing the scheduked lab proof within year of 2013. Further this drug design can move into in-depth primate test and experiments in comparisons to conventional treatments. This continuous efforts lead to US clinic trial targeting the revolutionary approach of powerful medicine treatment to anti drug-resistant TB infections, delivering a new formula to the most classical and serious worldwide market.

The experiments and test is under USDA conditional approval, under regulation and standard, as dedicated to safety and preparation of clinic trail stages toward a powerful new drug which is anti drug-resistant and regular Tuberculosis infection. All experiments are designed and conducted by a high-standard and internationally credible primate lab in UIC, and fully sponsored by Pheromonicin Biotech USA, Inc.

Infrastructure 信息菌素技术体系

信息菌素技术体系 Pheromonicin Technological Infrastructure

两大发明 和 一个平台  The Two Major Inventions with a Technological Platform

  • 发明 1:  The First Invention 利用大肠杆菌素和其他细菌的天然信息素连接构建新型抗生素药物
  • 发明 2:  The Second Invention 利用人工设计的抗体模拟物替代天然信息素构建新型信息菌素
  • 平台技术: It is a Platform Technology 利用细胞、抗体和基因工程快速筛选抗体模拟物和构建信息菌素新药的体系

Innovation 创新

  • 传统抗生素的抗菌原理(生物化学杀伤机制):是阻止细胞壁的形成,抑制或干扰蛋白质的合成,抑制或干扰细菌DNA的合成与复制。是生物化学过程。此方法生产的抗生素极易使细菌通过突变产生耐药性。
  • 信息菌素(Pheromonicin)的抗生原理:大肠菌素的抗菌原理(生物物理杀伤机制),由大肠杆菌产生的大肠菌素(Ia)在被攻击的细胞膜上形成致死性离子通道,使细胞内容物泄漏、能量耗竭造成细菌死亡。
  • 人工构建小型抗体模拟物替代天然信息素的研究结果为世界独创。

PBL 畿晋庆堂

PBL pioneers in a new era of the world biopharmaceutical industry

人造多结构域蛋白质分子机器,针对多结构细菌基高分子多肽的生物工程方法,研制新型抗生药物引领世界跨代生物制药科学趋向的创新发明。 Artificial Multi-domain Protein Machine, engineering multi-domain bactericidal peptide, a novel targeted antibiotic against antibiotic-resistant bacteria.
Continue reading

2012: Nature Biotech “Dealmakers” 《自然.生物技术》介绍信息菌素

Nature Biopharma Dealmakers 2012 《自然生物》技術交易


Engineering next-generation antibiotics drawn from natures toolbox

Pheremonicin Biotech’s platform for developing a progressive league of antibody mimetics provides distinct advantages and a new therapeutic approach to combating infectious diseases and other indications.
Continue reading